T2 Biosystems receives BARDA funding for diagnosis of bloodstream infections
T2 Biosystems announced that it has been awarded a milestone-based contract of initial value of $6M with a potential value of up to $69M, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services'. The contract will enable a significant expansion of the Company's current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes, which are designed to improve patient outcomes and reduce the growing threat of antimicrobial resistance. This contract will fund development through U.S. Food & Drug Administration submission of new direct-from-blood diagnostic panels that will be run on the T2Dx Instrument and the development of a next generation T2Dx Instrument:The first panel developed will be a direct-from-blood panel for detection of biothreat pathogens, including threats such as B. anthracis, F. tularensis, Burkholderia spp., Y. pestis, R. prowazekii, and toxin genes. The second panel is expected to cover 99% of all bloodborne bacterial infections by means of greater than or equal to36 reported results, which include pan-Gram positive and pan-Gram negative results, in addition to the bloodborne antibiotic resistant threats identified by the Centers for Disease Control and Prevention. Along with the new panels, the BARDA award supports the development of a next-generation high-throughput instrument.